๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study

โœ Scribed by Frank P.J. Peters; Roy I. Lalisang; Martin M.F. Fickers; Frans L.G. Erdkamp; Jacq A.J.M. Wils; Sjef G.J. Houben; Jaap Wals; Harrie C. Schouten

Publisher
Springer
Year
2001
Tongue
English
Weight
48 KB
Volume
80
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase II trial of bisantrene in patients
Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas
โœ Thomas P. Miller; Stephen E. Jones; David S. Alberts; Cindy Mackel ๐Ÿ“‚ Article ๐Ÿ“… 1984 ๐Ÿ› Springer US ๐ŸŒ English โš– 239 KB

Sixteen heavily pretreated patients with advanced intermediate and high-grade diffuse non-Hodgkin's lymphoma (NHL) were treated with 260 mg/M2 of bisantrene every three weeks. Thirty infusions of bisantrene were given without evidence of objective response. Pain in the infused arm, with or without s

Alternating chemotherapy regimen (P-VABE
Alternating chemotherapy regimen (P-VABEC) for intermediate and high-grade non-Hodgkin's lymphoma of the middle aged and elderly
โœ Dr. F. Caracciolo; M. Petrini; E. Capochiani; F. Papineschi; G. Carulli; B. Gras ๐Ÿ“‚ Article ๐Ÿ“… 1994 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 463 KB ๐Ÿ‘ 1 views

An intensive third generation regimen (P-VABEC) including adriamycin, etoposide, cyclophosphamide. vincristine, bleomycin and prednisolone was administered to 43 unselected elderly patients with intermediate or high-grade non-Hodgkin's lymphomas (NHL). The median age was 67, 40 per cent were Ann Arb